ACRS Aclaris: רווח למניה בשנים עשר החודשים האחרונים

Aclaris Therapeutics specializes in the development of immunological agents. The trailing 12-month EPS allows for an assessment of financial stability, where the value of -0.58 reflects this status. The company's growth depends on the success of kinase inhibitors and deals with industry behemoths. The business is independent of economic cycles and is currently actively expanding its portfolio beyond dermatology.
פילוחים אנליטיים ודוחות נתונים של חברת Aclaris (ACRS)

Aclaris Therapeutics (ACRS) focuses on developing high-precision selective kinase inhibitors to combat immune inflammation, which will provide the company with significant pricing power upon bringing its drugs to market. By analyzing the TTM net income per share, an investor assesses the real efficiency of the business model through annual income adjusted for the impact of share issuance, allowing for the determination of the asset's fundamental margin of safety.